TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02448420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.
Study: NCT02448420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibody-Drug Conjugates
Description: 3.6 mg/kg iv every 3 weeks
Study: NCT02959944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib capsules administered orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone administered daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone administered daily
Study: NCT02520843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stromal vascular fraction (SVF)
Description: stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
Study: NCT02496897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-02.2 Vaccine
Description: Synthetic Peptide Hepatitis B Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-02.2 Vaccine
Description: Synthetic Peptide Hepatitis B Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-02.2 Vaccine
Description: Synthetic Peptide Hepatitis B Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-02.2 Vaccine
Description: Synthetic Peptide Hepatitis B Vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IC31® Adjuvant
Description: IC31® Adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IC31® Adjuvant
Description: IC31® Adjuvant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IC31® Adjuvant
Description: IC31® Adjuvant
Study: NCT04519684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Allogeneic bone marrow derived mesenchymal stem cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT04350840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: feedback
Description: feedback of optical diagnosis performance per 3 month
Study: NCT03428789

Intervention type: PROCEDURE
Intervention: Sensory nerve coaptation
Description: A recipient sensory nerve of the abdomen was reattached to a donor nerve in the chest area. The sensory branch of usually the 11th intercostal nerve was used as recipient nerve for nerve coaptation and the anterior cutaneous branch of the third intercostal nerve was used as donor nerve. Direct, end-to-end nerve coaptation was performed with two stitches.
Study: NCT01407640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allergy tests
Description: 1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
Study: NCT03454893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVR-RD-01
Description: Single IV infusion of between 3 - 20 x 10\^6 CD34+ cells/kg.
Study: NCT02071251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prospective wound complication protocol
Description: The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
Study: NCT00791479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution and Lifestyle Measures
Description: Subcutaneous injection once-weekly for up to 12 weeks
Study: NCT02867943

Intervention type: OTHER
Intervention: Effects of respiratory rate on gapCO2
Description: respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min

Intervention type: OTHER
Intervention: Effects of respiratory rate on gapCO2
Description: respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min

Intervention type: OTHER
Intervention: Effects of respiratory rate on gapCO2
Description: respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min

Intervention type: OTHER
Intervention: Effects of respiratory rate on gapCO2
Description: respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
Study: NCT03098251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D typing
Description: typing the patient with 3D typing system and give specific treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine typing
Description: typing the patient with routine typing system and give specific treatment
Study: NCT01814098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
Study: NCT02862483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Tamsulosin
Study: NCT04421729

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group sessions over 3 weeks
Description: Informational and educational group-mediated program for family members caring for a person living with dementia; 6 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group sessions over 6 weeks
Description: Informational and educational group-mediated program for family members caring for a person living with dementia; 3 sessions.
Study: NCT02683889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
Study: NCT00515294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeinated Alcoholic Beer
Description: Alcoholic Beer plus Caffeine Citrate powder.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Caffeinated Alcoholic Beer
Description: Alcoholic Non-Caffeinated Beer
Study: NCT03977194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 90 mg/m² D1, 8, 15, every 4 weeks
Study: NCT00515294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeinated Non-Alcoholic Beer
Description: Non-Alcoholic Beer plus Caffeine Citrate powder.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Caffeinated, Non-Alcoholic Beer
Description: Non-Alcoholic Beer
Study: NCT03977194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90 mg/m² D1, 8, 15, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg every 3 weeks
Study: NCT03678792

Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine/naloxone
Description: Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
Study: NCT01953679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Acetate
Study: NCT02534285

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: hearing protection
Description: Attenuation of hearing during surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing protection
Description: Attenuation of hearing during surgery
Study: NCT03855293

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rhexis protection shield
Description: In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation
Study: NCT01102699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, hrG-CSF
Description: Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
Study: NCT02101580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study: NCT02108184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential therapy 10 days
Description: (pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential therapy 14 days
Description: (pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy 10 days
Description: (pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy 14 days
Description: (pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
Study: NCT03513133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: working memory training
Description: Hierarchical cognitive training of the different components of working memory according to Baddeley model; 15 tasks are used addressing: the phonological loop (8 tasks), the visuospatial sketchpad (4 tasks) and the central executive 3 tasks). Task are given in a hierarchical order, according to each individual patient's deficits and improvement.
Study: NCT01795911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribasphere

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study: NCT03753191

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
Study: NCT05544279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education is given about the focused disease and its nursing care management
Study: NCT02296931

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Standard IV Saline Fluids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
Study: NCT02369198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TargomiRs
Description: TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected.
Study: NCT02943135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine in-situ gel
Description: lidocaine in-situ gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo in-situ gel
Description: placebo in-situ gel
Study: NCT04392427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
Description: Target population: any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.~* Sample size: will depends on sequential analysis until a significant effect will be detected with a maximum of 100 subjects in each arm.~* Randomization: subjects will be allocated to either arm by block randomization method with sealed opaque envelops. Each block will include 10 subjects (to be allocated randomly as 5 in each group)~* Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days
Study: NCT03685201

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange Juice1
Description: 100% Orange Juice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange Juice2
Description: 100% Orange Juice with enzyme-treated orange pomace fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Raw Orange
Description: Raw Orange
Study: NCT00338312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System
Description: testosterone patch (300 mcg/day) patch changed 2 times/week, for one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch changed twice a week for one year
Study: NCT01191944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole immediate release tablet
Description: 0.375mg-4.5mg(daily dose), three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramipexole extended release tablet
Description: 0.375mg-4.5mg, once a day
Study: NCT01708967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pretreatment method for transnasal endoscopy
Description: Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).~Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pretreatment method for transnasal endoscopy
Description: Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).~Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity.
Study: NCT02000765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 for Injection
Description: GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing \[14C\] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 Capsule
Description: GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing \[14C\] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
Study: NCT04015908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 325mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: oxycodone 5-10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet
Description: Percocet (oxycodone 5mg/acetaminophen 325 mg)
Study: NCT02143921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training intervention
Description: Intervention group service providers received intervention training
Study: NCT00755443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: Drug eluting stent implantation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bare metal stent
Study: NCT03783429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Digoxin tablets will be given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo tablets will be given orally
Study: NCT03935438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: The training program of cardiac rehabilitation, depending on the results of the patient's medical qualification, will consist of the following: free active exercises, isometric exercises, active exercises in relief with resistance, isotonic exercises, isokinetic exercises, active breathing exercises, active breathing exercises with resistance, balance exercises, general exercises- individual and in groups, interval training on a treadmill or cycling cycloergometer, continuous training on a treadmill or cycling cycloergometer, circuit training, walking training, march training with accessories, autogenic training, walking. The training program will last an average 2 weeks.
Study: NCT01620294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal wall closure
Description: triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical site infection
Description: triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
Study: NCT01443897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1,000 IU vitamin D2
Description: capsule containing 1,000 IU vitamin D2

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: 0 IU vitamin D2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo capsule
Description: 0 IU vitamin D2
Study: NCT02994667

Intervention type: DEVICE
Intervention: Permanent Pacemaker Placement
Study: NCT03491566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinic Pilates Group
Description: Clinical Pilates exercises include Hundreds, One Leg Stretch, Shoulder Bridge, One Leg Kick, Swimming , Double Leg Stretch, Swan Dive Circle , Arm Opening , Spine Twist , Roll Down exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Group
Description: Aerobic exercise with using an elliptical bike, or bike or treadmill under supervision of a physiotherapist.